Delving into the Latest Updates on GT-919 with Synapse

Overview

Basic Info

Drug Type

Molecular glue

Synonyms

Target-

Mechanism-

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesImmune System Diseases+ [1]

Active Indication

Hematologic NeoplasmsMultiple Myeloma

Inactive Indication-

Originator Organization

Biaoxin Biomedical Technology (Shanghai) Co., Ltd.

Active Organization

Biaoxin Biomedical Technology (Shanghai) Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价GT919用于治疗复发或难治性多发性骨髓瘤（rrMM）或复发或难治性非霍奇金淋巴瘤（rrNHL）的安全性、耐受性；探索剂量限制性毒性（DLT），确定最大耐受剂量（MTD）；次要目的：评价GT919在rrMM或rrNHL患者中的药代动力学（PK）特征；评价GT919在rrMM或rrNHL中的疗效；确定II期研究推荐剂量（RP2D）。

[Translation]

Primary purpose: To evaluate the safety and tolerability of GT919 in the treatment of relapsed or refractory multiple myeloma (rrMM) or relapsed or refractory non-Hodgkin's lymphoma (rrNHL); to explore dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD); Secondary purpose: To evaluate the pharmacokinetic (PK) characteristics of GT919 in patients with rrMM or rrNHL; to evaluate the efficacy of GT919 in rrMM or rrNHL; and to determine the recommended dose (RP2D) for Phase II studies.

Start Date03 Jul 2023

Sponsor / Collaborator

Biaoxin Biomedical Technology (Shanghai) Co., Ltd.

100 Clinical Results associated with GT-919

Login to view more data

100 Translational Medicine associated with GT-919

Login to view more data

100 Patents (Medical) associated with GT-919

Login to view more data

100 Deals associated with GT-919

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hematologic Neoplasms	Phase 1	CN	Biaoxin Biomedical Technology (Shanghai) Co., Ltd.	03 Jul 2023
Multiple Myeloma	Preclinical	CN	Biaoxin Biomedical Technology (Shanghai) Co., Ltd.	-